医美化妆品1月月报：江苏吴中爱塑美获批上市，珀莱雅新品源力面霜2.0添加XVII型重组胶原蛋白-20240215-开源证券-12页_995kb

Report Summary

The analysis focuses on the medical beauty and cosmetics sectors, summarizing key developments, market trends, investment recommendations, and risks for 2024 January.

Medical Beauty Highlights

• Industry Dynamics: Jiangsu Wuzhou's AestheFill, a regenerative filler, has been approved and shows promise in stimulating natural collagen regeneration. By 2027, the Chinese regenerative market could exceed CNY 10 billion. The sector emphasizes thinner margins overall but benefits from increasing consumer demand for advanced treatments.
• Market Overview: In January 2024, the medical beauty index saw minimal declines, with Jiangsu Wuzhou recording a -0.7% decline, indicating resilient market performance despite short-term slowdowns.
• Investment Recommendations: Suggested companies include Ami Beauty (for product and R&D strengths) and Langzhi Shares (through acquisitions and operational growth). Beneficial targets are recommended for further consideration.

Cosmetics Highlights

• Industry Dynamics: Perly Ayal introduced an upgraded Night Repair Cream with XVII-type recombinant collagen, promoting direct collagen replenishment. Recombinant collagen is gaining attention, potentially boosting consumer education and market growth.
• Market Overview: January 2024 online sales rose significantly (+570% on TMall and +1028% on Douyin), driven by Chinese New Year effects. Domestic brands performed strongly, with companies like Perly Ayal and Gree Beauty showing high growth.
• Investment Recommendations: Recommended companies include Perly Ayal (brand strength) and Runbo Biology (collagen expertise), with high-potential niches like child care products and strong product innovation opportunities.

Key Recommendations and Risks

• Investment Advice: Focus on diversified portfolios with emphasis on innovative R&D and operational efficiency, avoiding companies like Wumei Group due to performance gaps.
• Risk Factors: Involves consumer demand uncertainties, increased competition leading to potential price wars, and regulatory risks, such as policy changes that could impact industry growth.

The overall outlook supports strategies centered on regenerative and collagen-based innovations, with high confidence in structural opportunities within these sectors, while being cautious about external factors affecting consumption.